Objectives Disease‐modifying treatments (DMT s) constitute the largest direct medical cost
for multiple sclerosis (MS). This study aims at investigating predictors of the 10‐year …

The “MS in the 21st Century” initiative was established with the purpose of (1) defining how
multiple sclerosis (MS) treatment and standards of care should look in the 21st century;(2) …

Introduction Comparisons of healthcare utilization and expenditure among multiple sclerosis
(MS) disease-modifying therapies (DMTs) are limited. Methods In this retrospective cohort …

Background Considering the multiple treatments approved for multiple sclerosis (MS) by the
Food and Drug Administration (FDA) and European Medicines Agency (EMA), determining a …

Epidemiological data on primary progressive multiple sclerosis (PPMS) are scarce. This
study was aimed to evaluate the burden of PPMS in Italy with healthcare resources …

At two meetings of a Central European board of multiple sclerosis (MS) experts in 2018 and
2019 factors influencing daily treatment choices in MS, especially practice guidelines …

Background: There is a growing number of cohorts and registries collecting phenotypic and
genotypic data from groups of multiple sclerosis patients. Improved awareness and better …

Introduction: To estimate the value of interventions in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with costs …

Objectives Disease-modifying therapies (DMTs) can slow disease progression in multiple
sclerosis (MS). The objective of this study was to explore the cost-of-illness (COI) …

Background: As patients with multiple sclerosis (MS) require lifelong treatment, optimization
of therapy with respect to efficacy and safety is needed to limit long-term disease …